跳至主要内容
临床试验/DRKS00014051
DRKS00014051已完成不适用

Prospective assessment of the clinical outcome of patients with primary breast cancer who have been tested with the EndoPredict gene expression test - a prospective care research study (RESCUE, Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer) - RESCUE/NOGGO-B3

OGGO e.V.0 个研究点目标入组 1,191 人开始时间: 2018年4月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,191

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Informed consent
  • 2. Tested with EndoPredict within the previous 6 months before inclusion
  • 3. Patients with primary invasive breast cancer, Stage I/II
  • 4. ER-postive
  • 5. HER2-negative
  • 6. N0 or N1 (1-3 positive lymph nodes)

排除标准

  • 1. Inflammatory breast cancer
  • 2. Bilateral breast cancer
  • 3. Breast cancer in the last 10 years
  • 4. Other invasive malignancies in the last 5 years

研究者

发起方
OGGO e.V.

相似试验